Epitel — $26M Series B for Wireless EEG Monitoring

• Epitel, Inc., a Salt Lake City-based AI-driven wireless brain health company, closed a $26 million Series B financing on 28 July 2026, co-led by Catalyst Health Ventures and Genoa Ventures with participation from new and existing investors.¹
• The funding will expand commercial access to Epitel’s REMI Remote EEG Monitoring System, a wearable, wireless platform integrated with the REMI Vigilenz AI system for automated seizure-event detection.¹²
• REMI has received five FDA 510(k) clearances covering wireless EEG monitoring and AI-assisted event detection, with current labeling supporting patients as young as one year old.¹
• Capital will fund commercial infrastructure expansion, provider adoption, and growth in the ambulatory monitoring market, extending long-term seizure monitoring historically limited to specialized epilepsy centers to broader and younger patient populations.¹
• The same two investors, Catalyst Health Ventures and Genoa Ventures, previously co-led Epitel’s $12.5 million Series A in 2022, bringing the company’s disclosed venture funding to roughly $38.5 million plus over $7.5 million in earlier NIH and Epilepsy Foundation grants.²

Footnotes

1. https://www.businesswire.com/news/home/20260728724496/en/Epitel-Secures-$26-Million-Series-B-to-Expand-Remote-Wireless-EEG-Monitoring ↩ ↩² ↩³ ↩⁴

2. https://www.bioworld.com/articles/732930-epitel-raises-26m-for-wireless-eeg-system-for-seizure-monitoring ↩ ↩²